drugset / Trial / NCT03007160

A Study on the Effection of Potassium Citrate Extended-release Tablets on Urolithiasis Formation or Recurrence

NCT03007160

Phase 4 Unknown 2001 enrolled Dawnrays Pharmaceutical (Holdings) Limited
RandomizedParallel-groupOpen-labelPrevention

Summary

Assess the efficacy and safety of potassium citrate extended-release tablets on Urolithiasis formation or recurrence.

Timeline

Start
2016-07
Primary completion
2020-09
Completion
2020-09

Drugs

EvaluationDrugModalityDoseRoute
Subject POTASSIUM CITRATE ANHYDROUS Small molecule 1.08 g Oral

Indications